A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with... von Kothari, R., Doshi, M., Chaithanya, P.K., Thungappa, S.C., Kumar, A., Mallavarapu, K.M., Nagarkar, R., Mahobia, V., Bhatt, N., Priyadarshini, K.L., Gogia, A., Maksud, T., Prasad, S., Kandappan, V., Krishnappa, R.L., Shanthemarahalli Shivanna, P., Talreja, V., Shrivastava, R., Parmar, D.

Volltext

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metasta... von Kothari, Rushabh, Doshi, Maulik, Chaithanya, P.K., CT, Satheesh, Kumar, Anil, Mallavarapu, Krishna Mohan, Nagarkar, Rajnish, Mahobia, Vijay, Bhatt, Niraj, Priyadarshini, K.L., Gogia, Ajay, Maksud, Tanveer, Prasad, Saurabh, Velavan, K., L․K․, Rajeev, SS, Prakash, Talreja, Vikas, Kalra, Kaushal, Nemade, Bhushan, Dastidar, Aloke Ghosh, Gupta, Tarachand, Patil, Tushar, Bondarde, Shailesh, Patel, Pinakin, Gupta, Sudeep, Biswas, Ghanashyam, Vaghela, Manan, Mahato, Pinaki, Parekh, Honey, Kalloli, Mahesh, Shetty, Rachan, Prakash, Gaurav, Goel, Anil, Mandal, Srikrishna, Choudhury, Tamohan, Jain, Minish, Goswami, Chanchal, H․M․, Yathish Kumar, Mukherjee, K․K․, Shrivastava, Rahul, Parmar, Deven

Volltext